Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 1998

View Archived Issues

Company Profile: Telik

Xoma completes phase II enrollment in psoriasis study

Kosan enters research collaboration with J&J

Rhone-Poulenc Rorer's Estalis approved in 12 E.U. countries

Inex demonstrates effectiveness of new antisense drug

Perprazole filings to be made within a year

Diatide brings first Techtide product to market

Neutrophil inhibitor peptides available for licensing from RCT

Scientists report significant finding related to the genetics of insulin-dependent diabetes

Nicotinic acetylcholine receptor ligands from Pfizer for addictive and CNS disorders

Ono's new PGE2 derivatives show binding affinity for EP2 receptors

Trega concludes phase I testing of HP-228 inhalation formulation

Antiatherosclerotic compounds prepared by Bayer scientists

Lundbeck develops new antipsychotic agents acting on D1 receptors

Novel central 5-HT1A receptor agonists characterized in binding and animal studies

Erythromycin derivatives for Gram-positive infections disclosed by Hoechst Marion Roussel

Antiatherogenic activity of antioxidant BO-653 explored in animal models

Demegen's Peptidyl MIM compound D4B effectively treats infected wounds

Gene therapy targeting Tie2 receptor tyrosine kinase evaluated as antiangiogenic strategy

Promising preclinical findings reported for PI-88; phase I testing begins next month

5-HT2C agonist shows potential for treating OCD and depression

NCIC-CTG leads major international trial for new ovarian cancer compound

Matrix reports promising phase III results for IntraDose in breast cancer

LXR redirects resources to three strategic development programs

GeneMedicine receives NIH grant to pursue AAT Gene Medicine

Pharmos successfully completes phase II head trauma study

Oralin cleared for phase III trials in Ecuador; regulatory clearance expected by year-end

DepoTech and Chiron submit NDA for DepoCyt

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...